论文信息 - The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab - 字舞流文

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

A. Dingemans | J. Aerts | C. Ficorella | R. Chiari | R. Berardi | A. Cortellini | M. Di Maio | G. Mentrasti | L. Cantini | L. Nicolardi | S. Rinaldi | F. Pecci | E. Lenci | A. Lupi | A. Caglio | S. Aerts | V. Cognigni | V. Agostinelli | N. Ranallo | F. Paoloni